PAREXEL Continues Expansion of Site Alliance Network
Global network accelerates patient recruitment and clinical trial start-up times
PAREXEL announced the continued expansion of its clinical trial site alliance network, an extensive network of investigator sites and Site Management Organizations (SMOs) that enables PAREXEL to quickly access and enroll patient populations for clients’ clinical trials worldwide.
To address challenges in patient recruitment, PAREXEL developed its Site Alliance network, currently consisting of more than 180 members plus several SMOs, together providing access to approximately 6,000 investigators worldwide. The SMOs alone have a combined database of 7.5 million patients in more than 25 countries. The network is currently in all the major regions where PAREXEL runs clinical trials, and is expanding to 200 sites. The network’s size and scope fosters strategic collaboration between PAREXEL and sites on behalf of clients and ensures quality across multiple sites.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
